Biotech Values

[DewDiligence]

JAGX +56% on animal-health collaboration with LLY:

http://finance.yahoo.com/news/jaguar-animal-health-elanco-enter-100000136.html

Jaguar Animal Health, Inc. (JAGX) and Elanco US Inc., a subsidiary of Eli Lilly and Company (LLY), today announced an agreement to license, develop, and commercialize Canalevia™, a Jaguar drug product candidate under investigation for treatment of acute and chemotherapy-induced diarrhea (“CID”) in dogs.

…Under the terms of the Agreement, Jaguar will receive an upfront payment of $1.5 million and additional payments upon achievement of certain development, regulatory and sales milestones in an aggregate amount of up to $61 million payable throughout the term of the agreement; product development expense reimbursement, and royalty payments on global sales.

Even after today’s pop, JAGX is down 88% from its May 2015 IPO (#msg-113625541).